Halozyme Therapeutics (HALO) EPS (Weighted Average and Diluted) (2010 - 2026)
Halozyme Therapeutics (HALO) reported EPS (Weighted Average and Diluted) of $1.22 for Q1 2026, up 31.18% year-over-year from $0.93 in Q1 2025, and up 208.93% quarter-over-quarter from -$1.12 in Q4 2025.
Halozyme Therapeutics (HALO) EPS (Weighted Average and Diluted) (2010 - 2026) Analysis & Trends
Halozyme Therapeutics (HALO) has 16 years of EPS (Weighted Average and Diluted) data on file, last reported at $1.22 in Q1 2026.
- EPS (Weighted Average and Diluted) for Q1 2026 came in at $1.22, up 31.18% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.86 (down 23.94% YoY), and the FY2025 annual result was $2.56, down 25.36% from the prior year.
- EPS (Weighted Average and Diluted) climbed to $1.22 in Q1 2026 per HALO's latest filing, from -$1.12 in the prior quarter.
- Over five years, EPS (Weighted Average and Diluted) peaked at $1.43 in Q3 2025 and troughed at -$1.12 in Q4 2025.
- A 5-year average of $0.63 and a median of $0.61 in 2023 frame the typical range for EPS (Weighted Average and Diluted).
- The sharpest annual moves came in 2023 and 2025: EPS (Weighted Average and Diluted) soared 250.0% in 2023, then tumbled 205.66% in 2025.
- A 5-year view of EPS (Weighted Average and Diluted) shows it stood at $0.42 in 2022, then soared by 54.76% to $0.65 in 2023, then surged by 63.08% to $1.06 in 2024, then plunged by 205.66% to -$1.12 in 2025, then jumped by 208.93% to $1.22 in 2026.
- Business Quant data shows HALO's EPS (Weighted Average and Diluted) at $1.22 in Q1 2026, -$1.12 in Q4 2025, and $1.43 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | 3.06 |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | 0.00 |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | -0.61 |
| 10 | Halozyme Therapeutics | 8.24 Bn | 7.92 Bn | 297.47 Mn | 1.22 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.22 |
| Dec 31, 2025 | -1.12 |
| Sep 30, 2025 | 1.43 |
| Jun 30, 2025 | 1.33 |
| Mar 31, 2025 | 0.93 |
| Dec 31, 2024 | 1.06 |
| Sep 30, 2024 | 1.05 |
| Jun 30, 2024 | 0.72 |
| Mar 31, 2024 | 0.60 |
| Dec 31, 2023 | 0.65 |
| Sep 30, 2023 | 0.61 |
| Jun 30, 2023 | 0.56 |
| Mar 31, 2023 | 0.29 |
| Dec 31, 2022 | 0.42 |
| Sep 30, 2022 | 0.44 |
| Jun 30, 2022 | 0.16 |
| Mar 31, 2022 | 0.43 |
| Dec 31, 2021 | 0.46 |
| Sep 30, 2021 | 1.48 |
| Jun 30, 2021 | 0.62 |